Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $25.00 price objective on the stock.

Milestone Pharmaceuticals Stock Down 60.9 %

NASDAQ MIST opened at $0.88 on Friday. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $46.95 million, a price-to-earnings ratio of -1.09 and a beta of 1.83. Milestone Pharmaceuticals has a 1-year low of $0.75 and a 1-year high of $2.75. The stock’s 50 day moving average is $2.00 and its two-hundred day moving average is $1.83.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Large investors have recently bought and sold shares of the business. Toronto Dominion Bank bought a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at about $1,770,000. Cubist Systematic Strategies LLC bought a new position in shares of Milestone Pharmaceuticals in the fourth quarter worth about $73,000. Boxer Capital Management LLC bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $729,000. Northern Trust Corp increased its holdings in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after purchasing an additional 30,772 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Milestone Pharmaceuticals in the 4th quarter valued at $80,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.